BUZZ-China's Gan & Lee Pharmaceuticals heads for biggest drop in a year on lower Q1 results

BRIEF-Gan & Lee Pharmaceuticals 2025 Net Profit Up 86.1% Y/Y

Gan & Lee Pharmaceuticals Gets Nod to Trial GLR1062 Injection

Gan & Lee Pharmaceuticals' Subsidiary Doses First Subject for Phase III of GZR33 Injection Trial; Shares Up 3%

BRIEF-Gan & Lee Pharmaceuticals - Signs Exclusive License Agreement With Jw Pharmaceutical

Gan & Lee Pharmaceuticals - Parties to Collaborate, Others on Clinical Development in South Korea of Bofanglutide Injection

Gan & Lee Pharmaceuticals Gets Regulatory Approval for Diabetes Combo Drug

Gan & Lee Pharmaceuticals Doses First Patient in Prostate Cancer Drug Trial

Gan & Lee Pharmaceuticals Advances GLR2037 Tablet to Phase I Clinical Trial Stage with First Patient Dosed

Gan & Lee Pharmaceuticals Subsidiary Secures GMP Certification from Brazilian Health Authority

Gan & Lee Pharmaceuticals - Once-Weekly Gzr4 Shows Favorable Safety Profile With No Severe Hypoglycemic Events

Gan & Lee Pharmaceuticals - Once-Weekly Gzr4 Reduces Annual Injection Frequency by More Than 85% Compared to Once-Daily Insulins

Gan & Lee Pharmaceuticals - Gzr4 Injection Shows Superior Hba1c Reduction Versus Lantus and Tresiba After 26 Weeks

Gan & Lee Pharmaceuticals' Once-Weekly Basal Insulin Gzr4 Injection Meets Primary Endpoints in Two Pivotal Phase 3 Clinical Trials: Super-1 and Super-2

Gan & Lee Pharmaceuticals Gets Drug Trial Approval to Treat Obesity-Related Sleep Apnea

Gan & Lee Pharmaceuticals Gets Regulatory Nod for Prostate Cancer Drug Trials

Gan & Lee Pharmaceuticals' Novel Targeted Protein Degradation Therapy Receives Clinical Trial Approval

Gan & Lee Pharmaceuticals Secures Clinical Trial Approval for GLR2037 Tablets

Gan & Lee Pharmaceuticals Expects 2025 Profit to Jump Up to 95%

Gan & Lee Pharmaceuticals (603087.SH) Issues Positive Profit Alert, Forecasts 2025 Net Profit Attributable to Owners to Increase 78.96% to 95.23% YoY